Promising Late-Stage Drugs Signal A New Treatment Era Delveinsight. The generalized myasthenia gravis treatment pipeline ...

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced new in vitro findings demonstrating that izicopan ...

Considering the debt-to-equity ratio in industry comparisons allows for a concise evaluation of a company's financial health and risk profile, aiding in informed decision-making.

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced that data from the Phase 3 study of vilobelimab ...

Alexion to deliver 20 presentations across gMG, NF1 plexiform neurofibromas and neuromyelitis optica spectrum disorder at AAN meeting: Cambridge, UK Saturday, April 11, 2026, 18:0 ...

Newer FDA-approved treatments for myasthenia gravis (MG) include FcRn blockers and complement inhibitors, which offer ...

Gov. Maura Healey proposed $227.3 million in additional spending Tuesday, mostly for snow and ice removal costs, in a bill ...

The fiscal year 2026 supplemental budget that Healey filed Tuesday afternoon seeks to make up the deficit left behind by a ...

EMPAVELI ® is a targeted C3 therapy designed to regulate excessive activation of the complement cascade, part of the body’s immune system, which can lead to the onset and progression of many serious ...

A 2026 informational overview of the Gel Water Diet System program, gel water weight loss trend, hydration and metabolism ...

A study published in Ageing Research Reviews and led by MA Yinzhong's team from the Shenzhen Institutes of Advanced Technology (SIAT) of the Chinese Academy of Sciences provided an integrated ...

President John Mahama has cautioned Ghanaians against the habit of eating heavy meals late at night. He warned that such ...